Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
about
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionHealth and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programmeEmerging experience with meningococcal serogroup B protein vaccines.Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.Neisseria meningitidis B vaccines: recent advances and possible immunization policies.Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.Fighting Neisseria meningitidis: past and current vaccination strategies.Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.Will booster doses be required for serogroup B meningococcal vaccine?Meningococcus B.Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
P2860
Q28080522-D7DEA457-B9C6-46A9-8761-D690EFED3762Q28391723-84A83E1D-395D-4078-A480-FB60CA6FFD12Q30234958-6236A615-1F6F-43AE-B4E2-B9BFE89E2B89Q30235040-F9C210EE-ED8A-4E35-97CB-C36BD99AF226Q35463235-36BC60CE-1383-4F89-99D0-5A7ACE401609Q35887617-86A39BFF-0967-4290-A0EF-DAF611EBBB8CQ35949585-B6F5A527-2423-4D15-8DE5-EB7BF5D2CDD6Q36206141-C79F2E3E-4880-48B8-81D5-CE182F5E2F5EQ37471668-44B5F8B4-176C-40CC-AF07-D1C96C50B1E3Q37563627-C7A0F57F-945E-467E-BA7B-9C3111B44387Q38183156-C1AB2316-2B84-4F2F-938E-F5353B7BB7E8Q38325374-0FCC81E1-83E6-422B-8190-1D9A0C1BBAF1Q38363907-DF8B6412-26C8-4338-B690-C31A7AADAF47Q38525922-047FF982-A9CE-46E2-8DF0-DB20D984BBD0Q38599522-1EFFF3DC-19BD-4804-BF82-666BC8D7B0B1Q38829564-BFB62C4E-1C85-48EC-B626-ACF2138F3B47Q40172533-304D57CB-0304-4723-A63F-03914E8AAF61Q40178578-DC67069A-D350-4F72-885B-8AB712DC9D5EQ40179042-07791577-2D40-408A-B50C-FA24B29A22F8Q40408137-53433964-AF28-4033-8488-93BEFFE8D799Q42678551-B65020AB-1E6D-404C-82BF-9722DA504BD0Q44496407-7EDADB41-3E7C-4B13-9B98-A3479A1326F6Q46520817-01E15E53-D350-4901-9B93-4ACB37F40A84Q54233532-F541EF6E-8F68-4DE1-ADEA-630E89CF752D
P2860
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistence of antibodies in a ...... ingococcal serogroup B vaccine
@en
Persistence of antibodies in a ...... ngococcal serogroup B vaccine.
@nl
type
label
Persistence of antibodies in a ...... ingococcal serogroup B vaccine
@en
Persistence of antibodies in a ...... ngococcal serogroup B vaccine.
@nl
prefLabel
Persistence of antibodies in a ...... ingococcal serogroup B vaccine
@en
Persistence of antibodies in a ...... ngococcal serogroup B vaccine.
@nl
P2093
P2860
P921
P356
P1476
Persistence of antibodies in a ...... ingococcal serogroup B vaccine
@en
P2093
Alma Muñoz
Daniela Toneatto
Gabriela Graña
Huajun Wang
Maria Elena Santolaya
María Teresa Valenzuela
Miguel O'Ryan
Peter M Dull
Rodrigo F Vergara
Valeria Prado
P2860
P304
P356
10.4161/HV.25505
P577
2013-06-28T00:00:00Z